Australia's MGC Pharmaceuticals jumps on FDA approval in Saudi Arabia
** Shares of Australia's MGC Pharmaceuticals MXC.AX rise
as much as 6.3% to A$0.51, their biggest intraday gain since
Nov. 16
** Stock posts its highest level since Dec. 13
** Biopharma co says it has been granted approval for its
proprietary product Artemic by the Food and Drug Authority in
the Kingdom of Saudi Arabia
** Artemic is a nutraceutical mouth spray that helps in
recovering from COVID-19 symptoms
** Still, stock down 95.6% YTD as of last close
(Reporting by Megha Rani in Bengaluru)
((Megha.Rani2@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program